2 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
Follow ecallantide: new trials by email Literature Review of ecallantide trials Research Report on ecallantide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema ecallantide 60 mg, ecallantide 30 mg, ecallantide 10 mg - ACE Inhibitor Induced Angioedema | Phase 2 | Terminated | Shire | 79 | 2011-06-01 | 2021-06-11 |
| Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement Ecallantide, Placebo - Blood Loss, Surgical | Phase 2 | Terminated | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 75 | 2007-05-01 | 2019-06-25 |
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Shire (1)
United States (2)